Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Goodwill & Intangibles (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Goodwill & Intangibles for 6 consecutive years, with $17.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Goodwill & Intangibles changed N/A year-over-year to $17.7 million, compared with a TTM value of $17.7 million through Sep 2025, changed N/A, and an annual FY2024 reading of $36.8 million, down 6.31% over the prior year.
  • Goodwill & Intangibles was $17.7 million for Q3 2025 at Cytek Biosciences, down from $35.3 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $43.8 million in Q1 2023 and bottomed at $476000.0 in Q2 2021.
  • Average Goodwill & Intangibles over 5 years is $20.4 million, with a median of $17.7 million recorded in 2025.
  • The sharpest move saw Goodwill & Intangibles soared 2031.09% in 2022, then plummeted 49.2% in 2024.
  • Year by year, Goodwill & Intangibles stood at $14.9 million in 2021, then dropped by 2.74% to $14.5 million in 2022, then surged by 171.27% to $39.3 million in 2023, then fell by 6.31% to $36.8 million in 2024, then crashed by 51.96% to $17.7 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for CTKB at $17.7 million in Q3 2025, $35.3 million in Q2 2025, and $36.8 million in Q4 2024.